Search Results for “AI” – Page 595 – media

A Chinese Province Is Sequencing One Million of Its Residents’ Genomes

Authorities in the city of Nanjing, the capital of China’s Jiangsu province, announced at the end of October that they would sequence the genes of 1 million individuals to build a genetic database of Chinese residents. This project is part of the National Health and Medicine Big Data Nanjing Center, a new data storage facility under construction in the region.
- Source: futurism
- 592
- November 10, 2017
cancer chronic gene Market Views sequence
POLICY CHANGE! Only 35 Days for New Drug Approvals!

Beijing Beishengyan biological Product’s Sabin Strain Inactivated Polioviurs Vaccine (Sabin IPV), secured approval from the China Food and Drug Administration (CFDA) in August 2017. On September 29th, Sabin IPV was officially on the market, offering one more option for IPV precaution. With the exception of time for material supplements, the CFDA took only 35 days to process production, registration and application of Beishengyan’s IPV and issue a drug approval number and certificate.
- Source: Ddu
- 700
- November 10, 2017
Ddu College drug approval IPV vaccine
12 Questions to Ask BEFORE Saying “Yes” to Chemotherapy Treatment

Conventional doctors have considered chemotherapy treatment and radiation to be the standard of care for so long, they’ve lost sight of the fact that these treatments are causing cancer − not curing it.   Did they somehow miss the fact that these super toxic cancer therapies could be the reason for their repeat customers?
- Source: thetruthaboutcancer
- 668
- November 10, 2017
cancer Chemotherapy
Two years in, the team at NousCom bags $49M to fund first human studies of neoantigen drugs

As NousCom CEO Alfredo Nicosia likes to say, the Basel-based biotech is a relative fledgling at 2-years of age. But the core research team there has been working together for quite a few years.
- Source: Endpts
- 585
- November 9, 2017
immune Market Views oncology vaccine
FDA Approves Genentech’s Alecensa Lung Cancer Treatment

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Alecensa (alectinib) for the treatment of people with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
- Source: Pharmpro
- 602
- November 9, 2017
ALK FDA New Approvals NSCLC sNDA
Breakthrough-Scientists reverse aging in human cells

New research published in the journal BMC Cell Biology shows that old human cells can be rejuvenated using chemicals similar to resveratrol, which is a substance found in red wine and dark chocolate.
- Source: medicalnewstoday
- 623
- November 9, 2017
cell Researches resveratrol
Mobile Digital health has the potential to save $46 billion a year in health spending

Existing digital health products hold the potential to save the nation $46 billion in healthcare spending if they’re deployed comprehensively, according to a new report from IQVIA, which on Tuesday renamed itself from Quintiles/IMS Health.
- Source: healthcareitnews
- 591
- November 9, 2017
asthma cardiac diabetes healthcare Market Views
FDA Lifts Clinical Hold on Cellectis Phase 1 Clinical Trials with UCART123 in AML and BPDCN

Cellectis (Alternext: ALCLS - Nasdaq: CLLS) a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold, previously announced on September 4, 2017, on Phase 1 trials of Cellectis’ UCART123 product candidate in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN).
- Source: Cellectis
- 565
- November 9, 2017
Cellectis Clinical Trials FDA immunotherapies UCART
7 Physical Symptoms of Depression

There is increasing evidence that the same mechanisms that cause depression in the brain can also affect other body systems as well. Here are seven physical symptoms that can be found alongside depression.
- Source: blogs.psychcentral
- 596
- November 9, 2017
bipolar depression Researches
EU OKs low-dose Xarelto to prevent recurrent VTE

A lower dose formulation of Bayer and Janssen’s bloodthinner Xarelto has been approved by European regulators for preventing recurrent venous thromboembolism, expanding treatment options for patients.
- Source: Pharmatimes
- 622
- November 8, 2017
cardiovascular New Approvals venous thromboembolism VTE

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.